Analyst Price Target is $13.00
▲ +692.68% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Surface Oncology in the last 3 months. The average price target is $13.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 692.68% upside from the last price of $1.64.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in Surface Oncology. This rating has held steady since August 2020, when it changed from a Hold consensus rating.
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.